First quarter 2017 report
Cash, cash equivalents and financial assets of the Company amounted to €223.8 million* ; Additional clinical data expected later in 2017. Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421...
Résultats financiers
2016: Operational progress and robust financial position for further growth
Cash, cash equivalents and financial instruments* amounted to €230.7m (million euros) as of December 31, 2016 Revenue and other income amounted to €65.7m (€25.1m in 2015), including $15m (€13.8m)...
Third quarter 2016 report
Cash, cash equivalents and financial assets amounting to €239.6 million [1] Continued progress with key clinical trials Safety data for lirilumab in combination in Phase I studies presented at the...
First half of 2016: building momentum through clinical development and new partnerships
Cash, cash equivalents and financial assets* for the Company amounted to €243.6m (million euros) as of June 30, 2016 Company is building foundations to become a commercial stage biopharmaceutical...
First quarter 2016 report
Cash, cash equivalents and financial instruments of the Company amounted to €255.8 million ; Broad innovative pipeline including three clinical-stage programs; expect first clinical data in 2016; Two...
Full-year 2015 financial results : Creating the platform for growth
Cash, cash equivalents and financial instruments amounting to €274 million*; Landmark co-development and commercialization agreement with AstraZeneca for monalizumab in immuno-oncology; Building...